Company: BDRX
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001214659-25-008576
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-30
Form: 424B3
Chunk 4
---
 Tumor Targeting Therapy, Int J Mol Sci. 2019 Feb; 20(3): 755

The Cancer Prevention and Research Institute of Texas
To date, CPRIT has awarded $2.9
billion in grants to Texas research institutions and organizations through its academic research, prevention and product
development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation
of 43 companies to Texas and generated over $5.7 billion in additional public and private investment. CPRIT funding
has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching
Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to provide
an additional $3 billion to CPRIT for a total $6 billion investment in cancer research and prevention. Learn more
at https://cprit.texas.gov/.

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing
a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs
include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development
for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.

eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR
(mammalian Target Of
Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling
pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.

Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the
Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue.
Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first
in class blood glucose modulating agent.

MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary